Press Releases

Press Release: Feb. 26, 2002
TheraLife^® invited to present clinical trial results for its unique treatment of dry eyes and eye fatigue at isopp meeting in spain.

TheraLife^®, Inc., an emerging leader in the discovery and development of cutting-edge drug enhancement technologies, today announced that Lily C. Yang, Ph.D., the company's CEO and President, has been invited to present the results of its clinical trial for a unique oral treatment of dry eyes and eye fatigue at the 4th International Symposium on Ocular Pharmacology and Pharmeceutics, Feb. 28 - Mar. 2, 2002 in Seville, Spain.

The International Symposium on Ocular Pharmacology and Pharmaceutics focuses on drug development and new drug applications. Sponsored by Eli Lilly, Pharmacia, Allergan, Novartis (Ciba Vision), Bausch & Lomb, Alcon, Santen, Senju Pharmaceuticals, Mitsubishi Parma Corporation, and Merck Sharp and Dohme, the conference will update ophthalmologists from around the world on clinical topics ranging from glaucoma, inflammation, infection, neuroprotection, and angiogenesis to blood flow and drug delivery.

"Blood flow and drug delivery are two unique aspects of our approach to the treatment of dry eyes and eye fatigue," said Dr. Yang. "We are very honored and excited to be a participant at the conference."

"TheraLife^® has developed an oral formulation that relieves dry eyes and eye fatigue in cases where conventional treatment modalities - including eye drops, such as artificial tears, and punctal plugs - have failed to produce lasting results," said Dr. Yang.

"One of the most scientifically provocative aspects of the just-completed clinical trial," explained Dr. Yang, "is the indication that our technology allows therapeutic agents in the blood to reach the eye, which previously has been virtually impossible to accomplish. The company's products - "TheraLife^® Enhancer" and "TheraLife^® Eye" - appear to be the only drug combination that is able to penetrate the so-called 'eye-blood barrier,' providing sustained relief through natural tear production."

Results from the six site, double blind, placebo-controlled clinical trial, conducted by leading optometrists and ophthalmologists in California and analyzed and tabulated by the Health Research and Studies Center, an independent clinical research organization, demonstrated significant improvement in eye dryness, tiredness, and contact lens discomfort as well as clinical improvement as measured by two standard tests: (1) the tear breakup test, and (2) the zone quick test. The TheraLife^® treatment also exhibited an excellent safety profile, with no significant systemic adverse safety findings.

"This breakthrough approach," said Todd D. Severin, M.D., a leading ophthalmologist specializing in the treatment of glaucoma and Assistant Clinical Professor at the University of California at Berkeley, "addresses a critical clinical need for the eye industry that potentially can lead to the treatment of other serious eye disorders - diabetic retinopathy, macular degeneration, glaucoma, and cataracts, for example - that can translate into an even more substantial health benefits."

Dr. Yang explained that TheraLife^®'s proprietary formulations were five years in development and use a unique combination of nutrients and phytochemicals to boost intracellular metabolism, membrane permeability and blood microcirculation to create their landmark effect. The ability of the formulation to function on a cellular level, she noted, has been scientifically demonstrated by independent testing.

About TheraLife^®
Based in Silicon Valley, California, TheraLife^® is a dynamic, emerging leader in the discovery and development of cutting-edge drug enhancement technologies. The company's mission is to offer superior products and breakthrough technologies that enable faster and more efficient delivery of ethical drugs, biopharmaceuticals and therapeutic agents with fewer side effects.

Note to Editors
Complete clinical trial results are available upon request. Free product samples are also available for you to try for the relief of dry eyes, eye fatigue, and computer vision syndrome. Please contact Emma Guyaz at (650) 917-1989.

Forward-Looking Statements
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this document should be evaluated together with the many uncertainties that affect our businesses, including results from clinical trials and other scientific studies, market trends and conditions, and a broad range of other business, financial and industry risks.

COMPANY CONTACT:
Lily C. Yang, PhD
CEO & President
TheraLife^®, Inc.
Tel: 650-917-1989
E-mail: lcyang@theralife.com

AGENCY CONTACT:
Richard Wood
Managing Partner
Sand Hill Partners
Tel: 650-631-0123
E-mail: partners@sandhillroad.com